English
French
German
Italian
Japanese
Portuguese
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022
myBinder
Alnylam Reports Positive Topline Results From APOLLO-B Phase 3 Study of Patisiran in Patients With ATTR Amyloidosis With Cardiomyopathy
myBinder
Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)
myBinder
Positive New Data From Phase 1/2 Trial of AT-01 (Iodine I-124 Evuzamitide) Presented at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
myBinder
Alnylam Announces FDA Approval of AMVUTTRA™ (Vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
myBinder
Alnylam Presents New 18-Month Results From Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
myBinder
oneAMYLOIDOSISvoice.com Support Group Platform Begins Empowering the Amyloidosis Community With Invaluable Info About Amyloidosis
myBinder
HealthWell Foundation Opens New Amyloidosis Fund to Assist Patients With Treatment Costs
myBinder
SCMR Partners With Foundation to Promote March as Amyloidosis Awareness Month
myBinder
Alexion Pharmaceuticals Partners With Caelum Biosciences to Tackle Light Chain Amyloidosis
myBinder
Hereditary amyloidosis in Brazil: a focus on access to diagnosis and treatment
myBinder
Amyloidosis, A Tricky Diagnosis, Can Be Traced to Vietnam and Exposure to Agent Orange
myBinder
With CRISPR Gene Editing, Unique Treatments Begin to Take off for Rare Diseases
myBinder
He Inherited A Devastating Disease. A CRISPR Gene-Editing Breakthrough Stopped It
myBinder
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
myBinder
The Orphan Drug Act Turns 40: NORD Celebrates Its Impact on Rare Diseases
myBinder
Health System First in Nation to Offer Treatment for Hereditary Amyloidosis
myBinder
Stem Cell Transplantation Produces Prolonged Survival With Improved Safety in Patients With AL Amyloidosis
myBinder
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
myBinder
Amyloidosis Support Groups Meeting – Arizona
myBinder
ATTR-Wild Type and Hereditary Amyloidosis Support Group Meeting October 27-29, 2023
myBinder
Amyloidosis Support Groups Meeting – Spokane
myBinder
CMAF Benefit Dinner: Evening of Corvettes, Dinner & Fun!
myBinderTo improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Community Key Collaborator
Support for this landing page is provided by an independent education grant from
Translation of this platform made possible through an independent education grant from
Powered by
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
